Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
McKinsey
Teva
Dow
Moodys
Medtronic
QuintilesIMS
Colorcon
Cerilliant
Chubb

Generated: August 18, 2017

DrugPatentWatch Database Preview

Cerexa Company Profile

« Back to Dashboard

What is the competitive landscape for CEREXA, and when can generic versions of CEREXA drugs launch?

CEREXA has two approved drugs.

There are twelve US patents protecting CEREXA drugs on CEREXA drugs in the past three years.

There are two hundred and seven patent family members on CEREXA drugs in fifty-seven countries.

Summary for Applicant: Cerexa

Patents:12
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CEREXA drugs

Drugname Dosage Strength Tradename Submissiondate
ceftaroline fosamil
Injection400 mg/vial and 600 mg/vial
TEFLARO
10/29/2014

Non-Orange Book Patents for Cerexa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,580,424Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
7,638,529Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
8,829,191Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
7,732,610Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
9,062,053Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cerexa Drugs

Country Document Number Estimated Expiration
Mexico2012003730► Subscribe
Australia7775301► Subscribe
Eurasian Patent Organization200400981► Subscribe
Taiwan201317238► Subscribe
Poland365162► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cerexa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 00120823
2016037Lithuania► SubscribePRODUCT NAME: CEFTAZIDIMAS + AVIBAKTAMAS; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
13/001Ireland► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
C0008France► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL, SES ESTERS OU SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
0568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Colorcon
Cipla
Fish and Richardson
Deloitte
Citi
Express Scripts
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot